# Vertex Pharmaceuticals Inc / Ma: overview

VRTX · Nasdaq · CIK 875320 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vrtx.md) · [Financials](/companies/vrtx/financials.md) · [Filings](/companies/vrtx/filings.md) · [Insiders](/companies/vrtx/insiders.md)

Latest reported revenue: [$3.33bn](/filings/0000875320-26-000259.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000875320-26-000259).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,772](/filings/0000875320-25-000232.md) | [2,912 d](/filings/0000875320-26-000056.md) | [2,770](/filings/0000875320-26-000173.md) | [2,965](/filings/0000875320-26-000259.md) | [3,076](/filings/0000875320-25-000232.md) | [3,190 d](/filings/0000875320-26-000056.md) | [2,987](/filings/0000875320-26-000173.md) | [3,334](/filings/0000875320-26-000259.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [40.3%](/filings/0000875320-25-000232.md) | [35.2% d](/filings/0000875320-26-000056.md) | [22.7%](/filings/0000875320-26-000173.md) | [38.8%](/filings/0000875320-26-000259.md) | [38.6%](/filings/0000875320-25-000232.md) | [37.8% d](/filings/0000875320-26-000056.md) | [38.1%](/filings/0000875320-26-000173.md) | [37.4%](/filings/0000875320-26-000259.md) |
| Net margin | % | [37.7%](/filings/0000875320-25-000232.md) | [31.4% d](/filings/0000875320-26-000056.md) | [23.3%](/filings/0000875320-26-000173.md) | [34.8%](/filings/0000875320-26-000259.md) | [35.2%](/filings/0000875320-25-000232.md) | [37.3% d](/filings/0000875320-26-000056.md) | [34.5%](/filings/0000875320-26-000173.md) | [33.0%](/filings/0000875320-26-000259.md) |
| Diluted EPS | $ per share | [4.01](/filings/0000875320-25-000232.md) | not reported | [2.49](/filings/0000875320-26-000173.md) | [3.99](/filings/0000875320-26-000259.md) | [4.20](/filings/0000875320-25-000232.md) | not reported | [4.02](/filings/0000875320-26-000173.md) | [4.31](/filings/0000875320-26-000259.md) |
| Free cash flow | $m | [1,302 d](/filings/0000875320-25-000232.md) | [492 d](/filings/0000875320-26-000056.md) | [778](/filings/0000875320-26-000173.md) | [927 d](/filings/0000875320-26-000259.md) | [1,140 d](/filings/0000875320-25-000232.md) | [349 d](/filings/0000875320-26-000056.md) | [1,295](/filings/0000875320-26-000173.md) | [1,013 d](/filings/0000875320-26-000259.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [7.6](/filings/0000875320-24-000062.md) | [8.9](/filings/0000875320-25-000053.md) | [9.9](/filings/0000875320-26-000056.md) | [11.0](/filings/0000875320-26-000056.md) | [12.0](/filings/0000875320-26-000056.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [36.7%](/filings/0000875320-24-000062.md) | [48.2%](/filings/0000875320-25-000053.md) | [38.8%](/filings/0000875320-26-000056.md) | [(2.1%)](/filings/0000875320-26-000056.md) | [34.8%](/filings/0000875320-26-000056.md) |
| Net margin | % | [30.9%](/filings/0000875320-24-000062.md) | [37.2%](/filings/0000875320-25-000053.md) | [36.7%](/filings/0000875320-26-000056.md) | [(4.9%)](/filings/0000875320-26-000056.md) | [32.9%](/filings/0000875320-26-000056.md) |
| Diluted EPS | $ per share | [9.01](/filings/0000875320-24-000062.md) | [12.82](/filings/0000875320-25-000053.md) | [13.89](/filings/0000875320-26-000056.md) | [(2.08)](/filings/0000875320-26-000056.md) | [15.32](/filings/0000875320-26-000056.md) |
| Free cash flow | $bn | [2.4](/filings/0000875320-24-000062.md) | [3.9](/filings/0000875320-25-000053.md) | [3.3](/filings/0000875320-26-000056.md) | [(0.8)](/filings/0000875320-26-000056.md) | [3.2](/filings/0000875320-26-000056.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vrtx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $12.97bn | 26,115,014 |  | Added +746,890 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $11.98bn | 24,109,373 |  | Added +139,856 |
| [Capital Research Global Investors](/funds/1422848.md) | 2026-06-30 | $9.68bn | 19,490,637 |  | Reduced −1,635,327 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.24bn | 16,580,713 |  | Added +67,903 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $5.90bn | 11,871,459 |  | Added +141,320 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $4.00bn | 8,043,052 |  | Added +5,481,995 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $3.26bn | 6,517,600 |  | Reduced −515,556 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.98bn | 6,017,848 |  | Reduced −121,773 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $2.42bn | 4,878,987 |  | Reduced −266,622 |
| [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $2.33bn | 4,695,144 |  | Reduced −430,933 |

## Recent filings

[All 2,708 filings](/companies/vrtx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-20 | 20:09 ET | [8-K](/filings/0000875320-26-000278.md) | 5.02 Departure or appointment of officers or directors | 0000875320-26-000278 |
| 2026-09-01 | 20:25 ET | [8-K](/filings/0000875320-26-000264.md) | 5.02 Departure or appointment of officers or directors | 0000875320-26-000264 |
| 2026-08-04 | 20:08 ET | [10-Q](/filings/0000875320-26-000259.md) | Quarterly report, period 2026-06-30 | 0000875320-26-000259 |
| 2026-08-03 | 20:09 ET | [8-K](/filings/0000875320-26-000256.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-26-000256 |
| 2026-07-07 | 01:55 ET | [8-K](/filings/0001193125-26-296710.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-296710 |
| 2026-05-13 | 20:03 ET | [8-K](/filings/0000875320-26-000204.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0000875320-26-000204 |
| 2026-05-05 | 20:08 ET | [10-Q](/filings/0000875320-26-000173.md) | Quarterly report, period 2026-03-31 | 0000875320-26-000173 |
| 2026-05-04 | 20:05 ET | [8-K](/filings/0000875320-26-000171.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000875320-26-000171 |
| 2026-04-29 | 20:05 ET | [8-K](/filings/0000875320-26-000166.md) | 5.02 Departure or appointment of officers or directors | 0000875320-26-000166 |
| 2026-04-02 | 20:02 ET | [DEF 14A](/filings/0000875320-26-000153.md) | Proxy statement, period 2026-05-13 | 0000875320-26-000153 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000875320-26-000056.md), filed Feb 13, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e1f666b0-b91e-4c39-ba5f-e6f5f20e1c26)

## About the filer

- CIK: 875320
- Tickers: VRTX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: MA
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:26 ET. No prices; not investment advice.